newsfilter
← Latest News
GlobeNewswire·

Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the